CAMK2N1, characterized as an inhibitor of CaMKII (calcium/calmodulin-dependent protein kinase II) [32–35], has been identified as a downstream transcriptional target of PRMT5 in PCa cells. The gene discussed is PRMT5; the disease is posterior cortical atrophy.